{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T14:16:43Z","timestamp":1791123403965,"version":"4.1.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,9,1]],"date-time":"2012-09-01T00:00:00Z","timestamp":1346457600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1016\/j.canlet.2012.03.021","type":"journal-article","created":{"date-parts":[[2012,3,23]],"date-time":"2012-03-23T19:48:24Z","timestamp":1332532104000},"page":"127-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages"],"prefix":"10.1016","volume":"322","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2012.03.021_b0005","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7326\/0003-4819-131-3-199908030-00008","article-title":"Chronic myelogenous leukemia: biology and therapy","volume":"131","author":"Faderl","year":"1999","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.canlet.2012.03.021_b0010","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMra020777","article-title":"Chronic myeloid leukemia-advances in biology and new approaches to treatment","volume":"349","author":"Goldman","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.03.021_b0015","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/shem.2003.50034","article-title":"Molecular mechanisms of transformation by the BCR\u2013ABL oncogene","volume":"40","author":"Sattler","year":"2003","journal-title":"Semin. Hematol."},{"key":"10.1016\/j.canlet.2012.03.021_b0020","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR\u2013ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0025","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs STI571(IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML\u2013CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0030","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1002\/cncr.11831","article-title":"Imatinib mesylate therapy improbe survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data","volume":"98","author":"Kantarjian","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.03.021_b0035","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1200\/JCO.2010.32.0598","article-title":"Tolerability-adapted imatinib 800mg\/d versus 400mg\/d versus 400mg\/d plus interferon-alpha in newly diagnosed chronic myeloid leukemia","volume":"29","author":"Hehlmann","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.03.021_b0040","doi-asserted-by":"crossref","first-page":"3358","DOI":"10.1200\/JCO.2007.15.8154","article-title":"Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis","volume":"26","author":"de Lavallade","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.03.021_b0045","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-years follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.03.021_b0050","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.03.021_b0055","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increate risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0060","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0065","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual out come is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0070","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1002\/cncr.24418","article-title":"Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase","volume":"115","author":"Alvarado","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.canlet.2012.03.021_b0075","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood.V114.22.2196.2196","article-title":"Chronic myeloid leukemia (CML) patients with \u201csuboptimal\u201d response to imatinib (IM) according to European LeukemiaNet criteria have a poorer outcome with respect to \u201coptimal\u201d responders: a GIMEMA CML working party analysis","volume":"114","author":"Castagnetti","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1182\/blood.V112.11.334.334","volume":"112","author":"Hughes","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0085","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1200\/JCO.2009.25.3724","volume":"28","author":"Cortes","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2012.03.021_b0090","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2\u00b0 in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.03.021_b0095","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.03.021_b0100","doi-asserted-by":"crossref","unstructured":"H.M. Kantarjian, N.P. Shah, J.E. Cortes, M. Baccarani, M.B. Agarwal, M.S. Undurraga, J. Wang, J.J. Kassack Ipi\u00f1a, D.W. Kim, M. Ogura, C. Pavlovsky, C. Junghanss, J.H. Milone, F.E. Nicolini, T. Robak, J. Van Droogenbroeck, E. Vellenga, M.B. Bradley-Garelik, C. Zhu, A, Hochhaus. Dasatinib or imatinib in newly diagnosed chronic phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION), Blood (2011) Dec 9 (Epub ahead of print).","DOI":"10.1182\/blood-2011-08-376087"},{"key":"10.1016\/j.canlet.2012.03.021_b0105","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V118.21.451.451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk progression\u2014an update of the TIDEL-II trial","volume":"118","author":"Yeung","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0110","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1182\/blood-2008-12-191254","article-title":"Comparison of imatinib 400mg and 800mg daily in the front-line treatment of high risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study","volume":"113","author":"Baccarani","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2009.021246","article-title":"The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase","volume":"95","author":"Palandri","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.canlet.2012.03.021_b0120","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2011-02-336685","article-title":"Combination of pegylated IFN-aRb with imatinib increases molecular response rates in patients with low or intermediate-risk chronic myeloid leukemia","volume":"118","author":"Simonsson","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0125","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","article-title":"Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow up results","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0130","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica."},{"key":"10.1016\/j.canlet.2012.03.021_b0225","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1182\/blood.V118.21.2756.2756","article-title":"Early CP CML, nilotinib 400 mg twice daily frontline: beyond 3 years, results remain excellent and stable (A GIMEMA CML Working Party trial)","volume":"118","author":"Gugliotta","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0140","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood.V118.21.454.454","article-title":"Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia Chromosome (Ph)-positive chronic Myeloid Leukemia in early chronic phase (CML\u2013CP)","volume":"118","author":"Quintas-Cardama","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0145","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1182\/blood.V118.21.1700.1700","article-title":"Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase","volume":"118","author":"Pemmaraju","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0150","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1182\/blood.V118.21.452.452","article-title":"Nilotinib versus imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 36-month follow-up","volume":"118","author":"Saglio","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0155","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.canlet.2012.03.021_b0160","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.canlet.2012.03.021_b0165","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1182\/blood.V118.21.604.604","article-title":"Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia (CML) patients (pts) with stable undetectable Bcr\u2013Abl transcripts: results from the French CML group (FILMC)","volume":"118","author":"Rea","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0170","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib 8BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0175","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are in sensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0180","first-page":"121 396","article-title":"Human chronic myeloid leukemia stem cells are in sensitive to imatinib despite inhibition of BCR\u2013ABL activity","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.03.021_b0185","doi-asserted-by":"crossref","first-page":"4016","DOI":"10.1182\/blood-2006-11-057521","article-title":"Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells","volume":"109","author":"Jorgensen","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0190","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr\u2013Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0195","doi-asserted-by":"crossref","first-page":"36-57-3660","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.canlet.2012.03.021_b0200","first-page":"362","volume":"47","author":"Carter","year":"2010","journal-title":"The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol"},{"key":"10.1016\/j.canlet.2012.03.021_b0205","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)17945-8","article-title":"Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukemia and persistent residual disease: a multicentre observational trial","volume":"365","author":"Bocchia","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.canlet.2012.03.021_b0210","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1172\/JCI35660","article-title":"Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells","volume":"119","author":"Bellodi","year":"2009","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.canlet.2012.03.021_b0215","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"France Intergroupe des Leuc\u00e9mies My\u00e9lo\u00efdes Chroniques (Fi-LMC). Imatinib plus peginterferon alfa-2\u00b0 in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2012.03.021_b0220","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature07737","article-title":"Hedhehog signalling is essential for maintenance of cancer stem cells in myeloid leukemia","volume":"458","author":"Zhao","year":"2009","journal-title":"Nature"}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512002042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383512002042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:33:01Z","timestamp":1759591981000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383512002042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["S0304383512002042"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2012.03.021","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: Unmet needs, pitfalls and advantages","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2012.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}